iPSirius’s research contributions paint a detailed picture of the delicate balance between pluripotency and oncogenesis, underscoring the intertwined nature of pluripotent stem cells and cancer stem cells. The findings not only provide a foundational understanding of the genomic characteristics and tumorigenic potential of stem cells but also pave the way for their potential clinical applications, including as cancer immunotherapies.
iPSirius’ most recent research articles, relevant to our current disclosed therapeutic product IPVAC 1.0, are as follows:
A ground breaking article from from 2021, "Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy," authored by Kishi et al., delineates the breakthrough potential of iPSCs for therapeutics against aggressive tumors. The study provides pivotal insights into the shared protein expression between iPSCs and cancer stem cells, which could be harnessed to stimulate a robust immune response against triple-negative breast cancer. With a remarkable modification in the tumor microenvironment, the strategy improves survival rates and mitigates metastatic spread, setting the stage for a novel, universally applicable cancer immunotherapy.
In 2019, Griscelli et al. published the enlightening study, "Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations," in Oncotarget. This paper investigates the genomic integrity of iPSC, generated through varied reprogramming methods, and unveils copy number variations linked to oncogenesis. The research underscores the intricate links between pluripotency, reprogramming methods, and oncogenic alterations, emphasizing the need for rigorous genetic screening of iPSCs before clinical use.
Tosca et al. contributed to our understanding of genomic instability in human embryonic stem cells with their 2015 paper, "Genomic instability of human embryonic stem cell lines using different passaging culture methods," published in Molecular Cytogenetics. Comparing mechanical/manual and enzymatic/collagenase-IV dissociation methods, the team found similar genomic instability rates across both, reinforcing the need for comprehensive understanding of the causes of genomic instability in stem cell culture.
The 2014 paper, "A mesenchymal glioma stem cell profile is related to clinical outcome," by Balbous et al., published in Oncogenesis, delves into the complex landscape of glioma stem cells, studying their pluripotency and differentiation capabilities. The researchers pinpoint key pluripotency factors, correlating heterogeneity in GSC lines with the overall survival of GBM patients.
In 2012, Griscelli et al. published "Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells," in The American Journal of Pathology. This paper throws light on the tumorigenic risks associated with iPSCs generation and the importance of their evaluation before clinical application.
In our initial paper from 2008, "Human embryonic stem cells reveal recurrent genomic instability at 20q11.21," published in Nature Biotechnology, Lefort et al. unveil recurrent genomic instability in human embryonic stem cells under long-term culture, revealing significant overlap between pluripotent stem cells and cancer stem cells.